Grey Wolf Therapeutics: Funding, Investors & Team (Oct 2026)
The UK-based Grey Wolf Therapeutics was established by seasoned businessmen Tom McCarthy (Executive Chairman), formerly the President and CEO of Spinifex Pharmaceuticals, and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Grey Wolf Therapeutics focuses on immuno-oncology. Grey Wolf's strategy actively alters the tumour cells, exposing them to the immune system's attack and elimination rather than attacking the immune system. The neoantigen repertoire on tumour cells is being modulated as a result of our targeting of a crucial protein in the antigen presentation pathway, drastically boosting tumour visibility and broadening the application of immunotherapy in oncology. To generate a clinical candidate against a strongly validated target, Grey Wolf is collaborating with top academic and commercial drug research partners.
Grey Wolf Therapeutics has raised $99.0M across 2 funding rounds on record, the most recent a Series B of $50.0M announced in May 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Grey Wolf Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Grey Wolf Therapeutics Funding Rounds
Grey Wolf Therapeutics raised $49.0M in a Series B announced in Jan 2023.
1.3 years later, a Series B of $50.0M was announced in May 2024.
Grey Wolf Therapeutics Founders and Leadership Team
Contact details for the Grey Wolf Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Grey Wolf Therapeutics Funding Compared to Other Biotechnology Startups
Grey Wolf Therapeutics' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Grey Wolf Therapeutics in Biotechnology and Oxford
Companies Similar to Grey Wolf Therapeutics
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Grey Wolf Therapeutics Funding FAQs
What does Grey Wolf Therapeutics do?
The UK-based Grey Wolf Therapeutics was established by seasoned businessmen Tom McCarthy (Executive Chairman), formerly the President and CEO of Spinifex Pharmaceuticals, and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Grey Wolf Therapeutics focuses on immuno-oncology. Grey Wolf's strategy actively alters the tumour cells, exposing them to the immune system's attack and elimination rather than attacking the immune system. The neoantigen repertoire on tumour cells is being modulated as a result of our targeting of a crucial protein in the antigen presentation pathway, drastically boosting tumour visibility and broadening the application of immunotherapy in oncology. To generate a clinical candidate against a strongly validated target, Grey Wolf is collaborating with top academic and commercial drug research partners.
How much funding has Grey Wolf Therapeutics raised?
Grey Wolf Therapeutics has raised $99.0M across 2 rounds on record. The most recent is a Series B of $50.0M announced in May 2024.
When did Grey Wolf Therapeutics last raise funding?
Grey Wolf Therapeutics' most recent funding round on record is a Series B of $50.0M, announced in May 2024.
Who founded Grey Wolf Therapeutics?
FundedIQ lists Peter Joyce (Founder) at Grey Wolf Therapeutics.
Where is Grey Wolf Therapeutics headquartered?
Grey Wolf Therapeutics is based in Oxford, Oxfordshire, United Kingdom.
How many employees does Grey Wolf Therapeutics have?
Grey Wolf Therapeutics is in the 11-50 employee band.
How does Grey Wolf Therapeutics' funding compare to other Biotechnology startups?
Grey Wolf Therapeutics' latest round of $50.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Grey Wolf Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Grey Wolf Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.